Partial
Mostly Not Aligned
Patient Risk:
Low
Summary
The FDA label excerpts provided do not contain any information about EU approvals or dates, so the EU-approval-related claims cannot be supported or contradicted by the supplied FDA prescribing information. The only label-supported elements in the excerpts concern US indications and safety; these are not directly addressed by the claims.
Category Scores
Accurate Statements
None of the provided EU approval/date claims are supported by the supplied FDA label excerpts.
No FDA label excerpts provided include regulatory history for EU approval dates or approvals.
Unsupported Statements
Vijoice (alpelisib) received European Union approval by the European Commission on 24 September 2023.
The supplied FDA prescribing information excerpts do not mention EU approval or any EU approval dates.
The 24 September 2023 EU approval was for certain patients with PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer.
The supplied FDA label excerpts provided are for PROS (PIK3CA-Related Overgrowth Spectrum) and do not include an indication for HR-positive/HER2-negative advanced or metastatic breast cancer; additionally, they contain no EU approval details.
In the EU, the product can be used after the European Commission approval date of 24 September 2023.
The supplied FDA label excerpts do not contain any regulatory or usage statements tied to an EU approval date.
Contradictions
Important Omissions
FDA label-supported indication/dosing framework for VIJOICE (PROS in patients ≥2 years requiring systemic therapy; accelerated approval context) is not addressed by the EU-approval claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The claims are about EU regulatory approval timing and an EU indication; the FDA label excerpts provided do not support these statements. However, because the claims do not provide dosing instructions or direct safety-related recommendations, the immediate patient-safety risk from the text itself (relative to the provided excerpts) is limited.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Not Aligned
Primary Issue
Claims reference EU approval date and an EU breast cancer indication that are not present in the supplied FDA label excerpts.
Suggested Improvement
Use only label-supported FDA indications (PROS in patients ≥2 years who require systemic therapy) and label-supported safety/administration statements; omit EU approval date/indication claims unless the relevant documentation is provided.